ONCAlert | Upfront Therapy for mRCC
Videos  >  

Overcoming Challenges in Treating Patients With Triple-Negative Breast Cancer

Stacy L. Moulder, MD
Published Online:3:49 PM, Mon February 4, 2019

Stacy L. Moulder, MD, professor of breast medical oncology at The University of Texas MD Anderson Cancer Center, discusses the challenges in drug development for triple-negative breast cancer (TNBC), specifically in the neoadjuvant setting.

Approximately 50% of patients with TNBC are sensitive to standard chemotherapy, says Moulder, and they do not need the additional toxicities of certain investigational agents.

Using the Artemis platform, investigators are aiming to use imaging to identify which patients are likely to respond to treatment and have a complete response at the time of their surgery. In patients who do not respond, investigators then determine what subtype of TNBC they have in order to select the appropriate targeted therapy.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.